Agentix Corp. (AGTX)
OTC Markets OTCPK
Price as at 30 Sept 2026, 15:54 UTC. Quotes are delayed.
Fundamentals
Valuation and ratings
Agentix Corp. trades at $0.02. We do not hold enough of the inputs to value this company with the confidence the estimate implies, so we publish no fair value for it rather than a number we would not defend.
About Agentix Corp.
Agentix Corp., a clinical development stage company, focuses on the development and commercialization of novel therapeutics to treat metabolic diseases in the United States. It develops AGTX-2004, a peripherally-acting CB1 receptor antagonist that has demonstrated efficacy in animal models of obesity and type 2 diabetes mellitus; and AGTX-2003, a peripherally-acting CB1 receptor inverse agonist, which has demonstrated efficacy in animal models of obesity and non-alcoholic fatty liver diseases. The company has licensing agreement with National Health Research Institute and Research Triangle Institute. The company was formerly known as FairWind Energy, Inc. and changed its name to Agentix Corp. in June 2019. Agentix Corp. was founded in 2020 and is based in Dana Point, California.
Company profile, industry and headcount are as reported by our data provider and can lag a company's own filings by a reporting period. The annual report is the authority.
Common questions
Where does SteadyShares get its AGTX data?
Fundamentals for AGTX come from company filings and exchange data, as listed on OTC Markets OTCPK; institutional ownership comes from SEC 13F filings. The share price shown was last refreshed on 30 Sept 2026, 15:54 UTC and is delayed. Metrics we do not hold are left out of the page rather than estimated.
The full research page for AGTX, with financial statements, ownership detail, peer comparison and alerts, is free inside the app.
Data from company filings, exchange quotes and SEC EDGAR 13F disclosures. Quotes are delayed. Metrics we do not have are left out rather than estimated. Educational information, not financial advice.